Literature DB >> 21487445

Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families.

Mathieu Fiore1, Xavier Pillois, Paquita Nurden, Alan T Nurden, Frédéric Austerlitz.   

Abstract

The c.1544+1G>A substitution at the 5' splice donor site of intron 15 of the ITGA2B gene, called the French Gypsy mutation, causes Glanzmann thrombasthenia, an inherited hemorrhagic disorder transmitted as an autosomal recessive trait and characterized by an altered synthesis of the platelet αIIbβ3 integrin. So far, this mutation has only been found in affected individuals originating from French Manouche families, strongly suggesting a founder effect. Our goal was to investigate the origin of the French Gypsy mutation. We estimated the age of the mutation by a likelihood-based method that uses the length of the shared haplotypes among a set of patients. For this, we genotyped 23 individuals of Manouche origin; consisting of 9 Glanzmann thrombasthenia patients homozygous for the French Gypsy mutation, 6 heterozygous carriers and 8 homozygous wild-type individuals. They were genotyped for four single-nucleotide polymorphisms using high-resolution melting curve analysis, and for two CA repeats in the BRCA1 and THRA genes at chromosome 17, using fragment analysis gels. We found that a haplotype of five polymorphic loci covering a 4-cM region was strongly associated with the French Gypsy mutation, suggesting a founder effect. The estimated age of this founder mutation was 300-400 years (range 255-552 years). Thus, all carriers of the French Gypsy mutation c.1544+1G>A at intron 15 descended from a common ancestor 300-400 years ago.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487445      PMCID: PMC3179361          DOI: 10.1038/ejhg.2011.61

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  25 in total

1.  Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures.

Authors:  R d'Oiron; C Ménart; M C Trzeciak; P Nurden; E Fressinaud; M Dreyfus; Y Laurian; C Négrier
Journal:  Thromb Haemost       Date:  2000-05       Impact factor: 5.249

2.  Analysis of platelet membrane glycoprotein polymorphisms in Glanzmann thrombasthenia showed the French gypsy mutation in the alphaIIb gene to be strongly linked to the HPA-1b polymorphism in beta3.

Authors:  B Jacquelin; E Tuleja; T J Kunicki; P Nurden; A T Nurden
Journal:  J Thromb Haemost       Date:  2003-03       Impact factor: 5.824

3.  Rapid diagnosis of the French gypsy mutation in Glanzmann thrombasthenia using high-resolution melting analysis.

Authors:  Mathieu Fiore; Alan T Nurden; Christine Vinciguerra; Paquita Nurden; Xavier Pillois
Journal:  Thromb Haemost       Date:  2010-09-30       Impact factor: 5.249

4.  One founder/one gene hypothesis in a new expanding population: Saguenay (Quebec, Canada).

Authors:  E Heyer
Journal:  Hum Biol       Date:  1999-02       Impact factor: 0.553

5.  [Clinics and genetics of Glanzmann's thrombasthenia (author's translation)].

Authors:  J M Lévy; C Stoll; A Gardea; P Bigel
Journal:  Nouv Rev Fr Hematol       Date:  1976

6.  Detection by PCR and HphI restriction analysis of a splice site mutation at the 5' end of intron 15 of the platelet GPIIb (alpha IIb integrin) gene responsible for Glanzmann's thrombasthenia type I in Gypsies originating from the Strasbourg area.

Authors:  C de la Salle; A Schwartz; M J Baas; F Lanza; J P Cazenave
Journal:  Thromb Haemost       Date:  1995-09       Impact factor: 5.249

7.  A 13-bp deletion in alpha(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia.

Authors:  N Rosenberg; H Hauschner; H Peretz; R Mor-Cohen; M Landau; B Shenkman; G Kenet; B S Coller; A A Awidi; U Seligsohn
Journal:  J Thromb Haemost       Date:  2005-12       Impact factor: 5.824

8.  Increased incidence of Glanzmann's thrombasthenia in Jordan as compared with Scandinavia.

Authors:  A S Awidi
Journal:  Scand J Haematol       Date:  1983-03

9.  Prenatal diagnosis of Glanzmann thrombasthenia using the polymorphic markers BRCA1 and THRA1 on chromosome 17.

Authors:  D L French; B S Coller; S Usher; R Berkowitz; C Eng; U Seligsohn; H Peretz
Journal:  Br J Haematol       Date:  1998-07       Impact factor: 6.998

10.  Genetic studies of the Roma (Gypsies): a review.

Authors:  L Kalaydjieva; D Gresham; F Calafell
Journal:  BMC Med Genet       Date:  2001-04-02       Impact factor: 2.103

View more
  7 in total

1.  Clinical utility gene card for: Glanzmann thrombasthenia.

Authors:  Mathieu Fiore; Alan T Nurden; Paquita Nurden; Uri Seligsohn
Journal:  Eur J Hum Genet       Date:  2012-07-11       Impact factor: 4.246

2.  A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer.

Authors:  Carolina Pires; Inês Jorge Marques; Daniela Dias; Ana Saramago; Valeriano Leite; Branca Maria Cavaco
Journal:  Endocrine       Date:  2021-03-08       Impact factor: 3.633

3.  Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel.

Authors:  Justyne E Ross; Bing M Zhang; Kristy Lee; Shruthi Mohan; Brian R Branchford; Paul Bray; Stefanie N Dugan; Kathleen Freson; Paula G Heller; Walter H A Kahr; Michele P Lambert; Lori Luchtman-Jones; Minjie Luo; Juliana Perez Botero; Matthew T Rondina; Gabriella Ryan; Sarah Westbury; Wolfgang Bergmeier; Jorge Di Paola
Journal:  Blood Adv       Date:  2021-01-26

Review 4.  Glanzmann thrombasthenia: state of the art and future directions.

Authors:  Alan T Nurden; Xavier Pillois; David A Wilcox
Journal:  Semin Thromb Hemost       Date:  2013-08-08       Impact factor: 4.180

5.  αIIbβ3 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia.

Authors:  Lorena Buitrago; Augusto Rendon; Yupu Liang; Ilenia Simeoni; Ana Negri; Marta Filizola; Willem H Ouwehand; Barry S Coller
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-31       Impact factor: 11.205

6.  Glanzmann thrombasthenia in Pakistan: molecular analysis and identification of novel mutations.

Authors:  A Haghighi; M Borhany; A Ghazi; N Edwards; A Tabaksert; A Haghighi; N Fatima; T S Shamsi; J A Sayer
Journal:  Clin Genet       Date:  2015-07-15       Impact factor: 4.438

Review 7.  Profiling the Genetic and Molecular Characteristics of Glanzmann Thrombasthenia: Can It Guide Current and Future Therapies?

Authors:  Alan Nurden
Journal:  J Blood Med       Date:  2021-07-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.